CL2007003630A1 - Composicion farmaceutica que comprende vitamina c, vitamina e, luteina, zinc, acido graso omega-3 y cobre; metodo de elaboracion; y uso para el tratamiento y/o prevencion de la degeneracion macular relacionada con la edad (amd) y/o retinopatia diabet - Google Patents

Composicion farmaceutica que comprende vitamina c, vitamina e, luteina, zinc, acido graso omega-3 y cobre; metodo de elaboracion; y uso para el tratamiento y/o prevencion de la degeneracion macular relacionada con la edad (amd) y/o retinopatia diabet

Info

Publication number
CL2007003630A1
CL2007003630A1 CL200703630A CL2007003630A CL2007003630A1 CL 2007003630 A1 CL2007003630 A1 CL 2007003630A1 CL 200703630 A CL200703630 A CL 200703630A CL 2007003630 A CL2007003630 A CL 2007003630A CL 2007003630 A1 CL2007003630 A1 CL 2007003630A1
Authority
CL
Chile
Prior art keywords
vitamin
luteina
diabet
amd
elaboration
Prior art date
Application number
CL200703630A
Other languages
English (en)
Inventor
Georg Ludwing Kis
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38024441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2007003630(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2007003630A1 publication Critical patent/CL2007003630A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/30—Copper compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
CL200703630A 2006-12-15 2007-12-14 Composicion farmaceutica que comprende vitamina c, vitamina e, luteina, zinc, acido graso omega-3 y cobre; metodo de elaboracion; y uso para el tratamiento y/o prevencion de la degeneracion macular relacionada con la edad (amd) y/o retinopatia diabet CL2007003630A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06126261A EP1932521A1 (en) 2006-12-15 2006-12-15 Nutritional supplement composition for treatment of ocular diseases

Publications (1)

Publication Number Publication Date
CL2007003630A1 true CL2007003630A1 (es) 2008-08-08

Family

ID=38024441

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200703630A CL2007003630A1 (es) 2006-12-15 2007-12-14 Composicion farmaceutica que comprende vitamina c, vitamina e, luteina, zinc, acido graso omega-3 y cobre; metodo de elaboracion; y uso para el tratamiento y/o prevencion de la degeneracion macular relacionada con la edad (amd) y/o retinopatia diabet

Country Status (22)

Country Link
US (1) US20100028459A1 (es)
EP (2) EP1932521A1 (es)
JP (1) JP2010513248A (es)
KR (1) KR20090089473A (es)
CN (1) CN101557807A (es)
AR (1) AR064332A1 (es)
AU (1) AU2007331432A1 (es)
BR (1) BRPI0720046A2 (es)
CA (1) CA2672013A1 (es)
CL (1) CL2007003630A1 (es)
CO (1) CO6220929A2 (es)
EC (1) ECSP099516A (es)
GT (1) GT200900161A (es)
MA (1) MA30994B1 (es)
MX (1) MX2009006306A (es)
NO (1) NO20092633L (es)
PE (1) PE20081580A1 (es)
RU (1) RU2009126735A (es)
TN (1) TN2009000241A1 (es)
TW (1) TW200843725A (es)
WO (1) WO2008071775A1 (es)
ZA (1) ZA200903862B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8389504B2 (en) * 2008-05-08 2013-03-05 Mead Johnson Nutrition Company Prenatal dietary supplement
US20100159029A1 (en) * 2008-12-23 2010-06-24 Alcon Research, Ltd. Composition and nutritional supplements for improving ocular health and reducing ocular inflammatory response
US20110021465A1 (en) * 2009-07-23 2011-01-27 U.S. Nutraceuticals, Llc D/B/A Valensa International Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome
US20130011469A1 (en) 2009-07-23 2013-01-10 U.S. Nutraceuticals, Llc D/B/A Valensa International Krill oil and carotenoid composition, associated method and delivery system
US20130295171A1 (en) 2009-07-23 2013-11-07 U.S NUTRACEUTICALS, LLC d/b/a Valensa International Krill oil and reacted astaxanthin composition and associated method
US20110237548A1 (en) * 2009-07-23 2011-09-29 U.S. Nutraceuticals, Llc D/B/A Valensa International Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome using omega choline
TR201809213T4 (tr) * 2011-07-07 2018-07-23 Howard Foundation Holdings Ltd Kamaşma yetersizliğinin iyileştirilmesine yönelik yöntem.
US9381183B2 (en) 2012-07-18 2016-07-05 Physicians Recommended Nutriceuticals, Llc Methods for improving the quality of the meibum composition of meibomian glands
US10709680B2 (en) 2011-07-18 2020-07-14 Physicians Recommended Nutriceuticals, Llc Methods for treating dry eye
US9115078B2 (en) 2011-07-18 2015-08-25 Physicians Recommended Nutriceuticals, Llc Compositions for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands
US20210121430A1 (en) 2011-07-18 2021-04-29 Prn Physician Recommended Nutriceuticals, Llc Omega-3 fatty acid supplementation for use in treating dry eye
KR101629670B1 (ko) * 2011-09-12 2016-06-13 타소스 지오지우 질환을 치료하기 위한 오메가 지방산의 용도
CN102538980A (zh) * 2012-01-12 2012-07-04 杭州美盛红外光电技术有限公司 热像装置和热像拍摄方法
JP2016185939A (ja) * 2015-03-27 2016-10-27 ロート製薬株式会社 経口組成物
JP2016190829A (ja) * 2015-03-31 2016-11-10 ウィルファーム株式会社 活性型ｄｈａを含む製剤、強化食品、サプリメント並びに化粧品
JP6056114B2 (ja) * 2015-05-30 2017-01-11 富田製薬株式会社 油状物質含有粉末組成物
CN108208804A (zh) * 2018-01-05 2018-06-29 美博迪尔（北京）生物科技有限公司 一种缓解眼睛干涩、抵御蓝光损伤及保护眼底的组合物及其制备方法
CN108096288A (zh) * 2018-01-16 2018-06-01 南京圣诺生物科技实业有限公司 护眼片及其制备方法和应用
EP4117652A1 (en) * 2020-03-11 2023-01-18 Bausch + Lomb Ireland Limited Compositions and methods for eye health comprising very long chain fatty acids

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003003981A2 (en) * 2001-07-05 2003-01-16 Vital Basics, Inc. Compositions for improving mental performance
US6649195B1 (en) * 2002-07-11 2003-11-18 Vitacost.Com, Inc. Eyesight enhanced maintenance composition
WO2005027950A1 (en) * 2003-09-12 2005-03-31 Ray And Terry's Health Products, Inc. Eye nutritional supplement
US7887847B2 (en) * 2004-05-08 2011-02-15 Paul Jr Edward L Nutritional supplement for treatment of ocular diseases
DE202005012984U1 (de) * 2005-08-17 2005-11-24 W & B Pharmamarken Gmbh Arzneimittel- und Nahrungsergänzungsmittelkombinationen zur Behandlung von Augenerkrankungen
EP1962618A2 (en) * 2005-12-20 2008-09-03 Alcon Research, Ltd. Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision

Also Published As

Publication number Publication date
NO20092633L (no) 2009-07-10
RU2009126735A (ru) 2011-01-20
US20100028459A1 (en) 2010-02-04
GT200900161A (es) 2009-11-30
MX2009006306A (es) 2009-06-23
JP2010513248A (ja) 2010-04-30
MA30994B1 (fr) 2009-12-01
AR064332A1 (es) 2009-04-01
AU2007331432A1 (en) 2008-06-19
ECSP099516A (es) 2009-08-28
EP2094252A1 (en) 2009-09-02
TN2009000241A1 (en) 2010-10-18
ZA200903862B (en) 2010-05-26
TW200843725A (en) 2008-11-16
WO2008071775A1 (en) 2008-06-19
EP1932521A1 (en) 2008-06-18
CO6220929A2 (es) 2010-11-19
KR20090089473A (ko) 2009-08-21
BRPI0720046A2 (pt) 2013-12-24
CA2672013A1 (en) 2008-06-19
PE20081580A1 (es) 2009-01-01
CN101557807A (zh) 2009-10-14

Similar Documents

Publication Publication Date Title
CL2007003630A1 (es) Composicion farmaceutica que comprende vitamina c, vitamina e, luteina, zinc, acido graso omega-3 y cobre; metodo de elaboracion; y uso para el tratamiento y/o prevencion de la degeneracion macular relacionada con la edad (amd) y/o retinopatia diabet
BR112013015503A2 (pt) formulação localizada tópica, uso de uma formulação, e, método para tratamento ou profilaxia de infestação de parasita de um animal
CL2014000732A1 (es) Compuestos derivados heterociclicos para su uso en la prevencion o tratamiento de una infeccion por flavivirus; metodo para su preparacion; y composicion farmaceutica que los comprende.
BRPI0916456A2 (pt) composto e composição lipídicos e respectivos métodos de produção e usos (incluindo método de tratamento e de prevenção de doenças que utilizam os mesmos)
SV2009003299A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
CL2007002121A1 (es) Compuestos derivados de pirazoles, activadores de glucoquinasa; proceso de preparacion de dichos compuestos; composicion farmaceutica que comprende dichos compuestos; y uso para el tratamiento de enfermedades y/o trastornos metabolicos, tal como diab
UY31314A1 (es) Amidas heterociclicas y sus métodos de uso-976
CL2007003423A1 (es) Compuestos derivados de pirimidinas sustituidas; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de artritis reumatoidea, aterosclerosis, entre otras enfermeda
GT201200126A (es) Derivados de la cromenona con actividad anti-tumoral
CU20130069A7 (es) Derivados de 2,3-dihidroimidazo[1,2-c] quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermeddes asociadas a la angiogénesis
CL2008003096A1 (es) Compuestos derivados de piperidino-dihidrotienopirimidinas; inhibidores pde4; composicion farmaceutica que los comprende; y uso en el tratamiento de trastornos o enfermedades de las vias respiratorias o gastrointestinales, como tambien enfermedades inflamatorias de las articulaciones u ojos, entre otras.
UY29079A1 (es) Acidos fenoxiacéticos sustituidos, composiciones que los contienen, procedimientos de preparación y aplicaciones
WO2008116135A3 (en) Topical formulations having enhanced bioavailability
CR20110608A (es) Derivados de 1h-imidazo-[4,5-c]-quinolinona
CL2008000593A1 (es) Uso de compuestos derivados de heterociclos sustituidos; composicion farmaceutica que comprende a dichos compuestos y otros agentes activos; y su uso para tratar diabetes, enfermedad aterosclerotica de las arterias entre otras enfermedades.
CL2007003209A1 (es) Composicion que comprende una vacuna de flavivirus vivos atenuados; composicion que comprende un producto farmaceutico derivado de virus o proteina; un metodo para la elaboracion de una composicion terapeutica que comprende liofilizar las composicion
CL2015000462A1 (es) Composición fungicida y método para el control de las enfermedades de las plantas.
DOP2007000043A (es) Derivados de cromanol sustituidos y su uso
CR10229A (es) Derivados de 1,2,4,5,-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
CL2008000981A1 (es) Compuestos derivados de imidazolidin-carboxamida; composicion farmaceutica; procedimiento de produccion de la composicion farmaceutica; y uso en el tratamiento y/o prevencion de trastornos ateroscleroticos, de metabolismo de acidos grasos y en los qu
ECSP14013275A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
BRPI0919231A2 (pt) agonista de receptor de neuropeptídeo-2, composição farmacêutica que o compreende, seu uso e método para o tratamento ou profilaxia de enfermidades
CL2008000641A1 (es) Compuestos derivados de amidas sustituidas; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento del insomnio, disfuncion sexual, esquizofrenia, entre otras enferme
EP2142549A4 (en) ADENOSINE DERIVATIVES, METHODS OF THEIR SYNTHESIS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES THEREOF CONTAINING THEM AS AN ACTIVE SUBSTANCE
PE20150353A1 (es) Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, metodos para su preparacion, preparaciones farmaceuticas que los contienen, asi como su uso para la preparacion de medicamentos